IntuitionLabs
GxP validation and 21 CFR Part 11 compliance services for Suvoda IRT and RTSM in pharma clinical trials

GxP Validation & 21 CFR Part 11 Compliance for Suvoda

Risk-based validation aligned with GAMP 5, FDA Computer Software Assurance, EU Annex 11, and ICH E6(R3) GCP. URS through UAT, periodic review, inspection-ready evidence — for Suvoda IRT, RTSM, eConsent, and eCOA across global studies.

Our Suvoda Validation Services

Three packaged service tracks covering new study-build validations, re-validations, and ongoing compliance — all aligned with GAMP 5 Second Edition, FDA Computer Software Assurance, and ICH E6(R3).

New Study Builds
Initial Validation
Full URS-through-UAT validation for new Suvoda study builds. Risk-based, CSA-aligned, with automated regression test packs that pay back across the study lifecycle and future amendments.
Plan validation
Existing Studies
Re-Validation & Remediation
Bring legacy or under-validated Suvoda studies up to current GAMP 5 and 21 CFR Part 11 expectations — including 483 and warning letter remediation programmes and inspection-readiness audits.
Discuss remediation
Ongoing
Periodic Review & Managed Compliance
Annual periodic review, amendment validation, change control review, integration regression testing, and inspection support delivered as a fixed-fee retainer or embedded resource model.
Managed compliance

Aligned with GAMP 5 Second Edition

Every validation deliverable maps cleanly to ISPE GAMP 5 Second Edition — the recognised framework for computerised systems in regulated life sciences. We document the categorisation decision per component (Category 4 for configuration, Category 5 for bespoke), scope validation effort accordingly, and revisit on every change. The output is proportionate validation — heavy where risk is high, light where it isn't — instead of the boilerplate over-validation that plagues legacy programmes.

GAMP 5 Second Edition validation framework applied to Suvoda IRT and RTSM for pharma and biotech

Built for Global Inspectors

The validation evidence pack is structured to mirror the questions inspectors actually ask. We integrate the latest expectations from recent FDA data integrity warning letters, EU Annex 11, MHRA data integrity guidance, and PMDA conventions for Japan studies — so the narrative aligns with what inspectors care about right now, not what was current ten years ago.

Inspection-ready validation evidence for Suvoda covering FDA, EMA, MHRA, and PMDA expectations

Risk-Based, CSA-Aligned Testing

FDA's Computer Software Assurance draft guidance shifts validation from documentation volume to critical thinking and risk-based assurance. We use unscripted testing for low-risk features, scripted testing for high-risk GxP-impacting functionality (randomization, supply, code break), and automated regression for everything that should be machine-checked. The result is a leaner deliverable that consumes much less sponsor time while remaining defensible.

Risk-based Computer Software Assurance approach to validating Suvoda study builds with automated regression testing

What Validation Looks Like in Practice

Six core deliverables that make up a complete Suvoda study-build validation package — adjusted for scope and risk, not photocopied between studies.

Validation Plan & Risk Assessment

Top-of-stack document defining scope, methodology, GAMP 5 categorisation per component, and the risk register that drives test depth. Approved by Quality before any other artefact is finalised.

Discuss planning

URS, FRS & Configuration Specs

Traceable specification chain derived from the protocol — User Requirements through Functional and Configuration Specifications — so every UAT step traces back to a regulated requirement and forward to evidence.

Discuss specs

UAT Protocols & Test Execution

Risk-based UAT protocols covering randomization, supply, kit and visit logic, eConsent, eCOA, emergency unblinding, and integration paths. Automated regression test packs cover protocols that are run repeatedly across releases.

Discuss UAT

Traceability Matrix

Single source of truth linking URS items to specifications, test cases, executed evidence, and defects. Inspectors ask for it on day one of every meaningful audit; ours is generated and maintained from the test management tool, not hand-typed.

Discuss traceability

SOPs & Periodic Review

SOPs covering audit trail review, user access management, change control for mid-study amendments, code break management, backup and restore verification, and incident response. Periodic review template aligned with GAMP 5 and ICH Q9(R1).

Discuss SOPs

Validation Summary Report

Final sign-off document tying together every artefact, deviations, change controls, and outstanding risks accepted by Quality. The single document an inspector reads first to assess validation maturity for a Suvoda study.

Discuss VSR

Why IntuitionLabs for Validation

Validation done by people who also configure the system is dramatically more efficient than validation done by people who only write paper. We do both, on the same study build, with the same team.

Combined Build + QA

Same team configures, integrates, validates, and supports the study build — no handoff drift between implementation and validation deliverables.

CSA Native

Risk-based, leaner validation aligned with FDA CSA and GAMP 5 Second Edition. Inspection-defensible without boilerplate over-validation.

AI Validation Capable

We validate AI integrations on Suvoda with the same rigour as classic functionality — not as an unmanaged shadow IT layer.

Regulatory Frameworks We Cover

🇺🇸

21 CFR Part 11

Full Subpart B and C coverage — electronic record controls, audit trail requirements, electronic signature manifestations, and signature/record linking — explicitly mapped against Suvoda configuration and procedural controls.

🇪🇺

EU Annex 11

Risk management, supplier audit, validation, data, accuracy checks, data storage, audit trails, change and configuration management, business continuity, and electronic signature — addressed in a single integrated dossier alongside Part 11.

📚

GAMP 5 Second Edition

Categorisation, lifecycle, risk-based validation, supplier leveraging, and critical thinking applied per ISPE Second Edition guidance. The default operating model for every Suvoda study-build engagement we run.

🛡️

ICH E6(R3) GCP

Good Clinical Practice principles for trial integrity, blinding, electronic systems, and data integrity — addressed in the validation evidence pack alongside the broader GxP framework so trial conduct holds up to inspection.

🌐

MHRA & WHO Data Integrity

ALCOA+ data integrity addressed at the technical and procedural level. Audit trail isolation, time-zone neutrality, immutable versioning, and dual-control review baked into the validation evidence pack.

✅

FDA Computer Software Assurance

CSA principles applied throughout — unscripted testing for low-risk features, scripted testing for high-risk GxP functionality, automated regression for repeatability, and proportionate documentation that satisfies inspectors without consuming excess time.

Frequently Asked Questions

A complete validation deliverable for Suvoda covers the full study-build lifecycle defined in ISPE GAMP 5 Second Edition: validation planning and risk assessment, User Requirements Specification (URS) derived from the protocol, Functional and Configuration Specifications, design qualification, study-build verification, User Acceptance Testing (UAT) protocols covering randomization, supply, eConsent, eCOA, emergency unblinding, and integration paths, traceability matrix, validation summary report, SOPs, and periodic review framework. The depth of each artefact is risk-based, aligned with FDA Computer Software Assurance principles — heavy testing on functions that affect patient safety, lighter on low-risk configuration. We deliver an evidence pack that withstands FDA, EMA, MHRA, and PMDA inspection.
We produce an explicit 21 CFR Part 11 mapping that walks through Subpart B (Electronic Records, §11.10 closed-system controls) and Subpart C (Electronic Signatures, §11.50 manifestations and §11.70 signature-record linking) line by line, identifying for each requirement: how Suvoda addresses it, what configuration choices are required, and what procedural controls the sponsor must implement. The same mapping is repeated against EU Annex 11 and ICH E6(R3) GCP. The result is a single defensible compliance dossier rather than three parallel exercises.
Suvoda is configured rather than coded for the vast majority of customer use cases, placing it in GAMP 5 Category 4 (configured products). Where sponsors layer bespoke custom rules, custom integrations, or AI-enhanced forecasting that materially affects patient supply, those elements move into Category 5 (custom applications) and require correspondingly deeper validation. We document the categorisation decision per component, scope validation effort accordingly, and revisit on every change. This is how we keep validation effort proportionate to actual risk rather than blanket over-validating low-risk configuration.
For a standard parallel-group Phase II or III study build, validation completes in 6-10 weeks running in parallel with configuration. For complex oncology adaptive designs, master protocols, or multi-modality decentralized trials, plan for 10-18 weeks alongside the build. Mid-study amendment validation typically runs 2-4 weeks per amendment depending on scope, with a delta UAT pack that focuses test depth where the change actually lives. The risk-based approach — and intelligent reuse of Suvoda-supplied platform qualification documentation — is what compresses these timelines compared to traditional validation. We also push as much testing as possible into automated regression suites that pay back on every future change.
Data integrity validation focuses on the ALCOA+ principles described in MHRA GxP Data Integrity Guidance: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available. We test the technical controls (audit trail capture, time-stamp accuracy and time-zone neutrality, immutable versioning, audit trail isolation from administrator modification, blinding-aware logging) and the procedural controls (audit trail review SOPs, dual-control on emergency unblinding, password and access reviews). We also test failure modes — what happens when a code break is attempted by an unauthorized user, what happens during a depot integration outage — and document the system response with reproducible evidence.
Yes — FDA's Computer Software Assurance (CSA) draft guidance is the operating model we recommend for new Suvoda study-build validations and re-validations. CSA shifts emphasis from documentation volume to critical thinking, risk-based assurance activities, and unscripted testing for low-risk features — directly aligned with GAMP 5 Second Edition. The result is a leaner validation deliverable that satisfies inspectors while consuming much less sponsor time. We have run CSA-style validations on IRT and clinical-systems study builds and can demonstrate the artefacts with anonymised reference packs.
Integrations are validated as system components in their own right. For each interface we produce: an interface specification (what data, in what format, in which direction, with what error handling), a risk assessment, test cases covering happy path, edge cases, and failure modes (including network partition and partial-write scenarios between Suvoda and EDC), and a reconciliation strategy for periodic verification of data flows. ALCOA+ traceability follows the data across the boundary — for example, a dispensation record flowing from Suvoda into Medidata Rave retains the original Suvoda transaction reference, operator, and timestamp. This satisfies MHRA expectations for end-to-end data integrity.
Suvoda is delivered as SaaS, which changes the validation pattern but not the obligation. We follow the supplier-leveraged validation pattern in GAMP 5 — auditing Suvoda's quality management system, leveraging supplier-provided platform qualification where available, and focusing customer validation on study-build configuration, business processes, and integrations. Cloud-specific risks (release cadence, multi-tenancy, data location, vendor breach response) are addressed through a supplier audit, contractual SLAs, and a continuous monitoring plan. The principles are documented in ISPE GAMP IT Infrastructure guidance.
Periodic review on a defined cadence (typically annual or aligned with major Suvoda platform releases) checks that the validated state still holds — that change controls have been honoured, security configuration has not drifted, audit trail review SOPs are being executed, and that no new Suvoda releases or integration changes have introduced unvalidated behaviour. We provide a periodic review template aligned with GAMP 5 expectations and ICH Q9(R1) quality risk management. Where the review identifies regression risk, we trigger targeted re-qualification rather than full re-validation — keeping cost proportionate to risk.
Inspection-readiness is built in from day one. The validation evidence pack is structured to mirror the questions that inspectors actually ask — the FDA Title 21 inspection guides, EMA Annex 11, MHRA data integrity guidance, and PMDA expectations for Japan studies. We provide inspection-day support: pre-inspection mock interviews with study owners, a controlled binder of evidence indexed to inspector questions, and on-site SME availability during the inspection itself. Recent FDA data integrity warning letters and clinical-systems 483 patterns are factored into the evidence narrative.
Mid-study amendments demand delta validation, not full re-validation. Our amendment validation process covers an impact analysis on the existing study build, a change request linked to the original URS, configuration delta documented and configuration-controlled, a focused UAT pack that retests only what changed plus regression on adjacent functionality, and an updated traceability matrix. The change control framework is aligned with GAMP 5 and ICH Q9(R1) quality risk management. The resulting evidence is integrated into the original validation summary so the inspection narrative remains coherent.
AI components are validated as configured items aligned with GAMP 5 and the FDA draft guidance on AI in drug development. We version-pin every model and prompt, maintain a regression test pack covering known-good prompts, run a continuous evaluation harness that flags drift on every provider release, and document the human-in-the-loop approval pattern that keeps AI as a drafting and forecasting aid rather than an unsupervised actor. The evidence pack is integrated with the broader Suvoda validation rather than living in a separate AI silo. See our Suvoda AI integration service in detail.
Ready to Get Your Suvoda Study Build Inspection-Ready?
Ready to Get Your Suvoda Study Build Inspection-Ready? image

Ready to Get Your Suvoda Study Build Inspection-Ready?

Book a discovery session to scope a risk-based, CSA-aligned validation of your Suvoda study build — built to satisfy FDA, EMA, MHRA, and PMDA inspectors without boilerplate over-validation.

Book a Meeting

© 2026 IntuitionLabs. All rights reserved.

Privacy PolicyTerms of ServiceBook Meeting